Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Oct 27.
Published in final edited form as: Laryngoscope. 2026 Jan 14;136(6):2638–2647. doi: 10.1002/lary.70366

TGFβ/Smad2/3-Mediated Crosstalk Between Vocal Fold Fibroblasts and Myoblasts In Vitro

Masayoshi Yoshimatsu 1, Ryosuke Nakamura 1, Renjie Bing 1, Gary J Gartling 1, Aaron M Johnson 1, Ryan C Branski 1
PMCID: PMC13698595  NIHMSID: NIHMS2215036  PMID: 41532567

Abstract

Objectives:

Traditionally, disorders of the vocal fold (VF) mucosa and underlying musculature have been regarded as mutually exclusive entities. However, emerging evidence from other organ systems suggests mucosal and muscle compartments engage in reciprocal interactions with functional consequences. We hypothesized that similar crosstalk exists in the VF, whereby fibrotic mucosa influences adjacent muscle. To model this process, we stimulated human VF fibroblasts (HVOX) with TGF-β1, a central mediator of fibrosis, and examined the effects on rat VF myoblasts (rVF-Mbs), as well as reciprocal influences of rVF-Mbs on fibroblasts.

Methods:

HVOX fibroblasts were stimulated with 10 ng/mL TGF-β1, and the effects on rVF-Mbs were assessed using conditioned media and co-culture. Myotube formation was evaluated by immunofluorescence, and nuclear localization of Smad2/3 was examined in conditioned media experiments. qRT-PCR quantified transcripts related to myogenic differentiation and Smad2/3 signaling. ALK4/5 inhibition was performed in co-culture to test TGF-β/Smad2/3-signaling pathway involvement. Reciprocal effects were examined by changes in fibrogenic gene expression in HVOX fibroblasts.

Results:

Both conditioned media and co-culture suppressed myogenic differentiation in rVF-Mbs; increased inhibition was observed in co-culture, as indicated by reduced myotube formation, decreased Myh2 expression, and activation of Smad2/3 signaling. ALK4/5 inhibition abrogated these effects. Differentiating rVF-Mbs attenuated the fibrogenic phenotype of HVOX fibroblasts.

Conclusions:

Fibrotic VF mucosal cells can impair myogenic differentiation through TGF-β/Smad2/3-mediated fibroblast–myoblast crosstalk, and myogenic cells may exert reciprocal anti-fibrotic effects. These findings suggest mucosa–muscle interactions may contribute to VF pathology and highlight Smad2/3 as a potential therapeutic target.

Level of Evidence:

NA

Study Design:

In vitro.

Keywords: atrophy, crosstalk, fibroblast, fibrosis, myoblast, Smad, transforming growth factor, vocal fold, voice

1 ∣. Introduction

Voice disorders affect nearly 30 million individuals in the United States each year and are associated with direct medical expenditures exceeding $13 billion [1, 2]. These disorders are typically categorized as either mucosal or neuromuscular in origin. Within mucosal pathology, vocal fold (VF) scarring is characterized by fibrosis and aberrant extracellular matrix (ECM) deposition within the lamina propria. This process compromises the biomechanical integrity of the vibratory portion of the VFs, resulting in glottic insufficiency and altered phonatory physiology [3, 4]. Neuromuscular pathologies, including VF muscle atrophy secondary to denervation or senescence [5, 6], similarly disrupt phonatory function [7, 8]. Despite the substantial burden of these conditions, the underlying mechanisms of these distinct remodeling processes remain incompletely understood, and therapeutic modalities are largely palliative. This gap underscores the need to elucidate mechanisms of VF tissue remodeling.

Traditionally, disorders of the VF mucosa and underlying musculature have been regarded as discrete entities. However, evidence from other organ systems shows stromal–muscle interactions are functionally significant. In skeletal muscle, satellite cells coordinate regeneration with interstitial mesenchymal populations, including fibro/adipogenic progenitors (FAPs). These cells release paracrine cues such as IL-6 and IGF-1 that promote satellite cell differentiation [9, 10]. Connective tissue fibroblasts synthesize ECM, while reciprocal signals from satellite cells restrain fibroblast activity to prevent fibrosis [11]. When this balance is lost, fibroblast expansion and matrix deposition impair myogenesis and contribute to muscle atrophy [12]. In the myocardium, cardiomyocytes secrete factors such as angiotensin II that activate fibroblasts, which then produce ECM and paracrine signals that induce cardiomyocyte hypertrophy and fibrotic remodeling [13]. These paradigms highlight the dual nature of fibroblast–myogenic cell crosstalk: supportive in regeneration, yet inhibitory in pathology.

Our prior in vitro investigations substantiated this concept. We observed VF fibroblasts attenuated myogenic differentiation of VF myoblasts and, these myoblasts, in turn, modulated fibroblast phenotypes [14]. Additionally, we demonstrated that transforming growth factor-beta1 (TGF-β1), a canonical profibrotic cytokine [15], exerted a more pronounced inhibitory effect on VF myoblast differentiation than myostatin, a ubiquitous negative regulator of myogenesis [16] and this effect was mediated via Smad2/3 signaling [17].

In the present study, we sought to interrogate the effects of TGF-β1-stimulated VF fibroblasts on myogenic differentiation under fibrogenic conditions. Specifically, we treated rat VF myoblasts with conditioned media from TGF-β1-stimulated human VF fibroblasts during differentiation into myotubes. Similarly, co-culture experiments with TGF-β1-stimulated fibroblasts were conducted to assess the effects on myoblast differentiation as well as the reciprocal effects of myoblasts on fibroblast phenotypes. We hypothesized that myogenic differentiation is inhibited by exposure to TGF-β1-stimulated VF fibroblasts or conditioned media, reflecting substantive fibrogenic influence on muscle structure and function. Collectively, these data provide further evidence of bidirectional VF muscle–mucosa interactions, providing mechanistic insight into the complexity of etiologies underlying voice disorders. The concept of compartmental crosstalk has the potential to inform novel regenerative strategies for millions of patients with laryngeal disease and voice disorders.

2 ∣. Materials and Methods

2.1 ∣. Human VF Fibroblasts

An immortalized human VF fibroblast cell line, HVOX fibroblasts, created in our laboratory [18] was employed in this study and maintained using Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic (AB/AM) solution (Thermo, Waltham, MA) at 37°C, 5% CO2. HVOX cells at passage 16 were used for all experiments.

2.2 ∣. Isolation of Rat VF Myoblasts (rVF-Mbs)

All procedures were approved by the Institutional Animal Care and Use Committee at NYU Grossman School of Medicine. Myoblasts were isolated from five-month-old Sprague Dawley rats as described previously [17]. After euthanasia by CO2 inhalation, the larynx was excised and a posterior midline incision was made to expose the VF lumen. Under microscopic guidance, the VF mucosa was carefully removed using micro-scissors and a 22-gauge needle. The medial TA muscle was dissected free from adjacent cartilage and the lateral TA muscle, minced, and enzymatically digested at 37°C for 30 min in a solution containing 4 mg/mL Collagenase type I (Sigma-Aldrich, St. Louis, MO) and 3 mg/mL Dispase II (Sigma-Aldrich). The digestion mixture was then removed by centrifugation at 250 g for 5 min and the resulting cells were plated on Matrigel (Corning, NY)-coated culture dishes. Cells were cultured in growth media (GM) composed of DMEM supplemented with 20% FBS, 10% horse serum (HS), 2.5 ng/mL basic fibroblast growth factor (Sigma-Aldrich), 0.5% chicken embryo extract (Accurate Chemical and Scientific, Westbury, NY), and 1% AB/AM solution. Media was changed every 2 days. For passaging, cells were detached using 0.25% trypsin and 2 mM EDTA solution and subsequently incubated for 1 h on bovine type I atelocollagen-coated dish, a step that selectively removed fibroblasts by adhesion to the collagen. The remaining non-adherent cell fraction was collected and expanded on Matrigel-coated dishes. Experiments were conducted using three independent cell batches derived from three rats.

2.3 ∣. Induction of Myogenic Differentiation

Rat VF myoblasts (rVF-Mbs) at passage 9 were utilized for all experiments. Cells were plated onto Matrigel-coated 6-well plates and 8-well chamber slides at densities of 1.0 × 105 and 1.5 × 104 cells per well, respectively, and maintained in GM. Once confluent, the cells were rinsed twice with serum-free DMEM and then cultured in differentiation medium (DM) consisting of DMEM supplemented with 2% HS for up to 48 h.

2.4 ∣. Conditioned Media Experiment

HVOX cells were cultured on 100 mm petri dishes until confluent. After two washes with PBS, the media was replaced with serum-free DMEM for serum starvation. After 24 h, cells were treated with DMEM containing 10 ng/mL recombinant human TGF-β1 (Thermo) for 24 h. Subsequently, cells were washed twice with PBS and fresh DMEM was added for another 24 h to collect conditioned media from TGF-β1-treated cells, referred to as TSCM. Culture supernatants were centrifuged and filtered through a syringe filter (0.2 μm pore size) before being stored at -80°C until use. rVF-Mbs were seeded as described above. Upon confluence, cells were cultivated with 2 mL DM (control) or DM + TSCM with 2% HS. Cells were collected for transcriptional analyses and immunocytochemistry at 48 h.

2.5 ∣. Co-Culture of VF Fibroblasts and rVF-Mbs

HVOX fibroblasts were cultured in cell culture inserts with a 0.4 μm pore size (Corning) until confluence. After two washes with PBS, the media was replaced with serum-free DMEM for serum starvation. After 24 h, cells were treated with DMEM containing 10 ng/mL recombinant human TGF-β1 for 24 h. The inserts were subsequently washed twice with PBS and transferred into a six-well plate containing confluent rVF-Mbs. During co-culture, cells were maintained in DMEM with or without 1 μg/mL ALK4/5 inhibitor SB431542 (Sigma-Aldrich). After 48 h, rVF-Mbs were harvested for transcriptional analyses and immunocytochemistry, and HVOX cells were collected for transcriptional analyses.

2.6 ∣. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted from cells cultured in 6-well plates via the RNeasy Mini Kit (Qiagen, Valencia, CA) and reverse transcribed with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). PCR was performed using the TaqMan Gene Expression kit (Life Technologies, Waltham, MA) on a QuantStudio system (Applied Biosystems). The following TaqMan rat probes were used: Myf5 (Rn01502778_m1), Myog (Rn00567418_m1), and Myh2 (Rn01470656_m1) were selected to capture the continuum of myogenic differentiation, representing undifferentiated myoblasts, early differentiation, and late differentiation, respectively [19]. Ccn2 (Rn01537279_g1) and Serpine1 (Rn01481341_m1) were included as canonical downstream targets of TGF-β/Smad2/3 signaling [20, 21], enabling assessment of pathway activation. Fbox32 (Rn00591730_m1) and Trim63 (Rn00590197_m1) were analyzed as atrophy-associated ubiquitin–proteasome pathway genes indicative of catabolic signaling [22]. Rat Gapdh (Rn01462662_g1) served as a housekeeping gene. For human genes, TaqMan probes of COL1A1 (Hs00164004_m1), ACTA2 (Hs00426835_g1), FN1 (Hs01549976_m1), CCN2 (Hs01026927_g1), SERPINE1 (Hs00167155_m1) were used, and GAPDH (Hs02758991_g1) served as a housekeeping gene. These genes are well-recognized profibrotic markers COL1A1, ACTA2, and FN1 are well-recognized extracellular matrix and myofibroblast markers [23], and CCN2 and SERPINE1 function as TGF-β/Smad2/3-responsive profibrotic effectors in fibroblasts, enabling evaluation of fibroblast-specific fibrogenic responses [24, 25]. Collectively, this marker panel was selected to align gene expression analyses with the mechanistic pathways under investigation. The ΔΔCt method was employed for quantification of relative expression [26].

2.7 ∣. Immunocytochemistry for Myotube Formation

Myotube formation was evaluated under the same conditions as transcriptional analyses using 6-well plates. Following a single PBS rinse, cells were fixed with 4% paraformaldehyde (PFA) for 10 min on ice, permeabilized with 1% Triton X-100 in PBS for 10 min at room temperature (RT), and blocked with 1% bovine serum albumin (BSA) in PBS containing 0.05% Tween-20 (PBST) for 1 h at RT. Cells were incubated overnight at 4°C with mouse monoclonal anti-myosin heavy chain (MHC) antibody (1:500, R&D Systems) diluted in 1% BSA/PBST, followed by incubation with species-specific secondary antibodies (Thermo).

2.8 ∣. Immunocytochemistry for Smad2/3 Nuclear Localization

To assess nuclear localization of Smad2/3 and phosphorylated Smad2 and Smad3 (pSmad2 and 3), cells were seeded onto 8-well chamber slides (Thermo) at a density of 1.5 × 104 cells/well, incubated in DM for 24 h, and subsequently treated with 300 μL of TSCM or DM (control) for 1 h. Following a single PBS rinse, cells were fixed with 4% PFA for 30 min on ice, permeabilized with 1% Triton X-100 in PBS for 10 min at RT, and blocked with 1% BSA in PBST for 1 h at RT. Primary antibodies included mouse monoclonal anti-MHC (1:500, R&D Systems), goat polyclonal anti-Smad2/3 (1:500, R&D Systems), rabbit monoclonal anti-pSmad2 (1:100, Cell Signaling Technology), and rabbit monoclonal anti-pSmad3 (1:500, Cell Signaling Technology), each diluted in 1% BSA in Tris-buffered saline (pH 7.4) containing 0.05% Tween-20. After overnight incubation at 4°C, slides were rinsed with PBS and incubated with appropriate secondary antibodies and DAPI staining.

2.9 ∣. Imaging and Quantification

Images were acquired using the Axio Observer Z1 microscope (Zeiss). For quantification of MHC-positive myotube areas, nine fields per well (3.8 × 5.0 mm) were captured and analyzed using ImageJ software (NIH). For Smad2/3 nuclear localization, nuclear and perinuclear regions were defined based on DAPI staining using the auto-threshold function. Nuclear intensities of Smad2/3, pSmad2, and pSmad3 were compared to their respective perinuclear signals. Analyses were performed separately for MHC-positive and MHC-negative regions using five randomly selected fields per experiment.

2.10 ∣. Statistical Analysis

All statistical analyses were performed using EZR (ver. 1.68). An unpaired Student's t-test was used for two-group comparisons, and one-way ANOVA followed by Tukey's honestly significant difference test was used for three-group comparisons. Differences were considered statistically significant at p < 0.05. Field values from each experiment were averaged to yield a representative value, and three independent experiments (n = 3) were analyzed. To account for variability between independent experiments, statistical analyses were performed on experiment-level means. Image-based data (MHC-positive area and nuclear intensity) were normalized to the control of each experiment, and qRT-PCR data were analyzed as relative expression.

3 ∣. Results

3.1 ∣. Conditioned Media From TGF-β1-Stimulated VF Fibroblasts Suppressed Myogenic Differentiation via Smad2/3 Signaling

The experimental workflow is summarized in Figure 1. Sparse distribution of myotubes was observed in the TSCM group; the MHC-positive area reduced by 19.8% at 24 h (p = 0.009) and by 10.2% at 48 h (p < 0.001) relative to control (Figure 2A,B). TSCM markedly increased Smad2/3, pSmad2, and pSmad3 nuclear intensity in myotubes (Smad2/3 p = 0.009, pSmad2 p = 0.01, pSmad3 p = 0.005) and myoblasts (Smad2/3 p < 0.001, pSmad2 p = 0.005, pSmad3 p = 0.015) compared to control (Figure 2C,D). TSCM significantly upregulated Myf5 (p = 0.003). Myog and Myh2 were not affected by TSCM. In addition, TSCM significantly increased Ccn2 (p = 0.031) and Serpine1 (p = 0.017) expression, and elevated Fbox32 (p = 0.017) compared to control. Trim63 expression was unaffected (Figure 2E).

FIGURE 1 ∣.

FIGURE 1 ∣

Schematic overview of experimental design. Two in vitro paradigms were used to evaluate fibroblast–myoblast crosstalk. In the conditioned media paradigm, TGF-β1–stimulated human vocal fold (VF) fibroblast-derived conditioned media (TSCM) were applied to rat VF myoblasts, and Myosin heavy chain (MHC)-positive area, Smad2/3 nuclear localization, and gene expression were evaluated. In the co-culture paradigm, rat VF myoblasts and human VF fibroblasts were cultured together to assess bidirectional interactions, with gene expression quantified. Gene expression analyses included myogenic differentiation markers, muscle atrophy-related markers, and Smad2/3 signaling downstream markers in myoblasts, and extracellular matrix/profibrotic markers in fibroblasts.

FIGURE 2 ∣.

FIGURE 2 ∣

Immunocytochemical analysis and quantitative PCR analyses of myogenic differentiation and Smad2/3 activation in rat VF muscle-derived myoblasts (rVF-Mb) exposed to TSCM. Immunocytochemistry for MHC (red) at 48 h (A) and quantification of the MHC-positive area in control and TSCM groups at 24 and 48 h after induction of myogenic differentiation (B). Immunocytochemistry for Smad2/3 (gray), pSmad2 (magenta), and pSmad3 (green) after 1 h of TSCM exposure, counterstained with MHC (red) and DAPI (blue) (C). Nuclear intensity of Smad2/3, pSmad2, and pSmad3 in myotubes and myoblasts (D). Quantitative PCR analysis of Myf5, Myog, Myh2, Ccn2, Serpine1, Fbox32, and Trim63 at 48 h (E) (All values represent TSCM data relative to control (B, D: 100%; E: 1.0), Mean ± SD; N = 3 (B, D, E); *p < 0.05, **p < 0.01, ***p < 0.001).

3.2 ∣. Co-Culture With TGF-β1-Stimulated VF Fibroblasts Suppressed Myogenic Differentiation

Co-culture with TGF-β1-stimulated HVOX cells (TSHVOXs) reduced MHC-positive myotube area by 76.3% at 24 h (p < 0.001) and 69.1% at 48 h (p < 0.001) compared to control (Figure 3A,B). TSHVOXs significantly upregulated Myog (p = 0.001) and down-regulated Myh2 expression (p < 0.001). Furthermore, TSHVOXs significantly increased Ccn2 (p = 0.031) and Serpine1 (p = 0.017). Fbox32 and Trim63 expression were unchanged (Figure 3C).

FIGURE 3 ∣.

FIGURE 3 ∣

Immunocytochemical and quantitative PCR analyses of myogenic differentiation in rVF-Mb co-cultured with TGF-β1-Stimulated HVOX fibroblasts (TSHVOX). Immunocytochemistry for MHC at 48 h (A) and quantification of MHC-positive area in control and TSHVOX groups at 24 and 48 h (B). Quantitative PCR analysis of Myf5, Myog, Myh2, Ccn2, Serpine1, Fbox32, and Trim63 at 48 h (C). (All values represent TSHVOX data relative to control (B: 100%; C: 1.0), Mean ± SD; N = 3 (B, C); *p < 0.05, **p < 0.01, ***p < 0.001).

3.3 ∣. ALK4/5 Inhibitor Mitigated TSHVOX-Induced Suppression of Myogenic Differentiation

The ALK4/5 inhibitor SB431542 (SB) restored MHC labeling in co-culture with TSHVOXs. Significant differences were detected between SB-treated and untreated cells (SB+ and SB−) at 24 h (p < 0.001) and 48 h (p < 0.001; Figure 4A,B). SB significantly rescued TSHVOX-induced decrease in Myh2 expression (p < 0.001) and attenuated TSHVOX-induced increase in Ccn2 (p < 0.001), Serpine1 (p = 0.004), and Fbox32 (p = 0.049) expression, compared to treatment without SB (Figure 4C).

FIGURE 4 ∣.

FIGURE 4 ∣

Effect of the ALK4/5 inhibitor SB-431542 on TSHVOX-induced suppression of myogenic differentiation. Immunocytochemistry for MHC at 48 h (A) and quantification of MHC-positive area in SB-treated (SB+) and untreated (SB−) groups at 24 and 48 h (B). Quantitative PCR analysis of Myf5, Myog, Myh2, Ccn2, Serpine1, Fbox32, and Trim63 at 48 h (C). (Mean ± SD; N = 3 (B, C); *p < 0.05, **p < 0.01, ***p < 0.001).

3.4 ∣. Rat VF Myoblasts Attenuated the Fibrogenic Response of TGF-β1-Stimulated VF Fibroblasts

Expression of ACTA2, CCN2, SERPINE1, COL1A1, and FN1 was significantly activated by TGF-β1 stimulation in HVOX cells (p < 0.001). Co-culture with rVF-Mb markedly attenuated TGF-β1-induced upregulation of those genes (ACTA2, SERPINE1 and COL1A1: p < 0.001, CCN2 p = 0.002, FN1 p = 0.006; Figure 5).

FIGURE 5 ∣.

FIGURE 5 ∣

Inhibition of TGF-β1-induced fibrogenic response in HVOX by co-culture with rVF-Mb. Quantitative PCR analysis of ACTA2, CCN2, SERPINE1, COL1A1, and FN1. (Mean ± SD; N = 3; *p < 0.05, **p < 0.01, ***p < 0.001).

4 ∣. Discussion

Crosstalk between stromal and myogenic cells plays a crucial role in tissue remodeling in skeletal muscle [9-12] and the myocardium [13]. Given the anatomical continuity between the VF mucosa and the underlying TA muscle, interactions between these compartments may contribute to the progression of many aberrant phenotypes in the VFs, including fibrosis and/or muscle atrophy. Importantly, TGF-β1 expression increases in the epithelium and lamina propria during the acute phase of VF injury [27, 28]. We employed TGF-β1-stimulated VF fibroblasts to mimic the fibrogenic environment observed in VF injury and scarring, and investigated the impact of these stimulated fibroblasts on rVF-Mb differentiation to provide insight into mucosa–muscle crosstalk.

In this study, fibrogenic stimulation of human VF fibroblasts with TGF-β1 created a paracrine and extracellular environment that strongly suppressed myogenic differentiation of rVF-Mbs. Both conditioned media and co-culture had this anti-myogenic effect, as evidenced by reduced MHC-positive area and diminished Myh2 expression. These changes were accompanied by activation of Smad2/3 signaling, including increased nuclear localization of Smad2/3, pSmad2, and pSmad3, and induction of downstream targets such as Ccn2 and Serpine1. Pharmacologic inhibition of ALK4/5 abrogated these effects, underscoring involvement of TGF-β/Smad2/3 signaling in the atrophic phenotype. Notably, a reciprocal influence was also observed; differentiating rVF-Mbs attenuated the fibrogenic phenotype of VF fibroblasts. Taken together, these findings expand on our previous work demonstrating TGF-β1-mediated suppression of rVF-Mbs differentiation [17]; TGF-β/Smad2/3-mediated crosstalk at the mucosa–muscle interface is likely mechanistic for this response.

Our previous work first demonstrated bidirectional interactions between VF fibroblasts and myoblasts in a cell culture model, proposing fibroblasts suppress myogenesis while myoblasts attenuate fibrosis [14]. Our current findings are consistent with this concept, suggesting fibroblast-derived signals under TGF-β1 stimulation impair myogenesis. By using TGF-β1-stimulated VF fibroblasts, we modeled the fibrogenic environment associated with VF pathology. Importantly, differentiating myoblasts also reduce the fibrogenic phenotype of human VF fibroblasts, supporting reciprocal communication.

Findings from other organs exemplify the context dependency of fibroblast–myogenic cell interactions. In cardiac models, fibroblast-derived soluble mediators modulated cardiomyocyte hypertrophy and calcium transients, and these effects were partially suppressed by SB431542, indicating involvement of TGF-β signaling [29]. Similarly, in two-dimensional culture, human skin-derived fibroblasts activated by TGF-β1 inhibited the differentiation of C2C12 myoblasts derived from mouse skeletal muscle [30]. In contrast, in three-dimensional engineered constructs, TGF-β1-stimulated fibroblasts promoted myogenesis, underscoring the critical influence of microenvironmental context [30]. Likewise, embryonic skeletal muscle-derived fibroblasts enhanced myoblast survival and alignment, supporting myogenic progression [31].

Reciprocal influences of muscle cells on fibroblasts have also been reported. Myogenic progenitor cells secrete exosomal miR-206 that represses Rrbp1, an endoplasmic reticulum-associated ribosomal protein involved in the synthesis and secretion of multiple proteins, and its suppression results in reduced ECM deposition in fibroblasts [32]. In cardiac models, cardiomyocyte co-culture with fibroblasts yielded more complex regulation, attenuating FN1 but amplifying COL1A1 and ACTA2 expression under TGF-β1 stimulation [33]. Together with our present findings in the VF, these studies suggest muscle–fibroblast crosstalk is a fundamental but context-dependent feature, with outcomes shaped by tissue specificity, dimensionality of the culture system, and the surrounding molecular environment.

An additional observation in this study was clear nuclear accumulation of pSmad3 in VF myoblasts under fibroblast-conditioned media, which was not prominent after direct TGF-β1 exposure [17] . This difference suggests fibroblast-derived mediators, acting alongside TGF-β1, enhance Smad3 activation, reinforcing the notion that Smad2/3 signaling is modulated by paracrine inputs. The importance of fibroblast-derived mediators in TGF-β1 signaling has been reported in the lung, where periostin, a matricellular protein secreted by TGF-β1-stimulated fibroblasts, augmented Smad3 activation in neighboring cells [34].

From a translational perspective, our findings raise the possibility that age-related VF atrophy may not result from independent degeneration of the mucosa and the TA muscle, but rather from biological processes that transcend traditional compartmental boundaries. This concept challenges the dogma that mucosal fibrosis and muscle atrophy progress as separate phenomena. Mucosal fibrosis associated with conditions that elevate TGF-β1 after VF mucosal injury [27, 28] may have a substantive influence beyond the mucosa, potentially promoting an atrophic phenotype in the underlying medial TA muscle. Such interdependent pathology could exacerbate phonatory impairment by simultaneously stiffening the mucosa and reducing TA muscle volume, providing a mechanistic basis for glottic insufficiency. Current voice rehabilitation strategies primarily target phonatory efficiency and glottic closure and are suggested to positively affect the TA muscle [35]. Given that, in skeletal muscle, satellite cells are activated by exercise and differentiate into myoblasts [36-38], our findings that differentiating VF myoblasts exert anti-fibrotic effects suggest that enhancing myogenic activity could have implications beyond muscle integrity, potentially mitigating mucosal fibrosis. Voice rehabilitation, therefore, may offer benefits that extend beyond phonatory mechanics by harnessing myogenesis-associated effects on the VF tissue environment. These concepts warrant further in vivo validation.

Although mucosal fibrosis has already been linked to activation of the TGF-β/Smad2/3 pathway [18], our findings suggest this cascade may also mediate crosstalk across compartments. These insights raise the possibility that therapeutic strategies targeting Smad2/3 could have broader utility, addressing both mucosal fibrosis and its indirect effects on muscle function. In this context, modulation of the TGF-β/Smad2/3 pathway emerges as a promising approach. Preclinical studies have shown that soluble activin receptors [39, 40] and ligand-binding antagonists such as follistatin [41, 42] and decorin [43] can prevent skeletal muscle atrophy and anti-fibrotic effects by inhibiting the TGF-β/Smad2/3 pathway. Localized delivery of such agents to both lamina propria and TA muscle may maximize efficacy by simultaneously mitigating fibrosis and preserving muscle integrity.

Our in vitro model incorporates human VF fibroblasts and rat VF myoblasts to interrogate TGF-β–driven paracrine signaling. The core components of this pathway—including ligand structure, receptor architecture, and Smad-dependent intracellular cascades—are highly conserved across mammals [44], supporting the translatability of TGF-β–mediated effects beyond species boundaries. Heterologous co-culture systems have similarly been used to investigate fibroblast-mediated modulation of myogenesis—for example, murine myoblasts paired with human skin-derived fibroblasts—demonstrating functional interactions can be preserved across species [30]. From a practical standpoint, immortalized HVOX fibroblasts provide a stable and reproducible platform, whereas primary human VF myoblasts are not commercially available, and rat VF fibroblasts exhibit progressive senescence, limiting their suitability for multi-assay experimental designs. Collectively, these features support the suitability of our system for dissecting TGF-β-driven paracrine mechanisms in the VF microenvironment.

Several limitations must be acknowledged. First, this study was conducted entirely in vitro, and our models cannot replicate the full complexity of the in vivo environment. Clarifying how VF mucosal fibrosis influences adjacent TA muscle will require in vivo studies. Second, although TGF-β/Smad2/3 involvement was observed, this pathway does not operate in isolation. TGF-β/Smad signaling interacts with other pathways, including Wnt/β-catenin [45], which is implicated in both fibrotic remodeling [46] and myogenic regulation [47], suggesting that fibroblast–myoblast communication may be shaped by multiple interconnected mechanisms. Ultimately, these refinements will enable validation of fibroblast–myoblast crosstalk in vivo and inform the design of therapies to preserve muscle integrity while mitigating mucosal fibrosis.

5 ∣. Conclusion

Fibroblast-derived signals under TGF-β1 stimulation suppressed VF myoblast differentiation, while myoblasts reciprocally attenuated fibroblast fibrogenesis. These findings support the concept of bidirectional crosstalk between VF mucosa and muscle, providing a potential mechanistic basis for the clinical coexistence of fibrosis and atrophy. Although limited to in vitro models, this work represents a foundational step toward understanding intercompartmental interactions in the larynx and suggests therapeutic strategies targeting Smad2/3 may hold promise to mitigate both mucosal and muscular pathology.

Funding

This work was supported by the National Institutes of Health/National Institute on Deafness and Other Communication Disorders (R01DC021453 and R01DC020730).

Footnotes

Conflicts of Interest

The authors declare no conflicts of interest.

Portions of this work were submitted for presentation at the 147th Annual Meeting of the American Laryngological Association, Phoenix, AZ, Apr 22-26, 2026 (Abstract Entry ID: 26-0017).

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  • 1.Hong I, Bae S, Lee HK, and Bonilha HS, “Prevalence of Dysphonia and Dysphagia Among Adults in the United States in 2012 and 2022,” American Journal of Speech-Language Pathology 33 (2024): 1868–1879. [DOI] [PubMed] [Google Scholar]
  • 2.Cohen SM, Kim J, Roy N, Asche C, and Courey M, “Direct Health Care Costs of Laryngeal Diseases and Disorders,” Laryngoscope 122, no. 7 (2012):1582–1588. [DOI] [PubMed] [Google Scholar]
  • 3.Kumai Y, “Pathophysiology of Fibrosis in the Vocal Fold: Current Research, Future Treatment Strategies, and Obstacles to Restoring Vocal Fold Pliability,” International Journal of Molecular Sciences 20, no. 10 (2019): 2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Thibeault SL, Gray SD, Bless DM, Chan RW, and Ford CN, “Histologic and Rheologic Characterization of Vocal Fold Scarring,” Journal of Voice 16, no. 1 (2002): 96–104. [DOI] [PubMed] [Google Scholar]
  • 5.Martins RHG, Benito Pessin AB, Nassib DJ, Branco A, Rodrigues SA, and Matheus SMM, “Aging Voice and the Laryngeal Muscle Atrophy,” Laryngoscope 125, no. 11 (2015): 2518–2521. [DOI] [PubMed] [Google Scholar]
  • 6.Applebaum J, Harun A, Davis A, Hillel AT, Best SRA, and Akst LM, “Geriatric Dysphonia: Characteristics of Diagnoses in Age-Based Cohorts in a Tertiary Voice Clinic,” Annals of Otology, Rhinology, and Laryngology 128, no. 5 (2019): 384–390. [DOI] [PubMed] [Google Scholar]
  • 7.Omori K, Kojima H, Slavit DH, Kacker A, Matos C, and Blaugrund SM, “Vocal Fold Atrophy: Quantitative Glottic Measurement and Vocal Function,” Annals of Otology, Rhinology, and Laryngology 106, no. 7 II SUPPL. 169 (1997): 544–551. [DOI] [PubMed] [Google Scholar]
  • 8.Song JS, Campbell R, Lin RJ, and Jeffery CC, “Laryngoscopic Findings of Age-Related Vocal Fold Atrophy Are Reliable but Not Specific,” Clinical Otolaryngology 47, no. 4 (2022): 516–520. [DOI] [PubMed] [Google Scholar]
  • 9.Joe AWB, Yi L, Natarajan A, et al. , “Muscle Injury Activates Resident Fibro/Adipogenic Progenitors That Facilitate Myogenesis,” Nature Cell Biology 12, no. 2 (2010): 153–163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Heredia JE, Mukundan L, Chen FM, et al. , “Type 2 Innate Signals Stimulate Fibro/Adipogenic Progenitors to Facilitate Muscle Regeneration,” Cell 153, no. 2 (2013): 376–388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, and Kardon G, “Satellite Cells, Connective Tissue Fibroblasts and Their Interactions Are Crucial for Muscle Regeneration,” Development 138, no. 17 (2011): 3625–3637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Farup J, Madaro L, Puri PL, and Mikkelsen UR, “Interactions Between Muscle Stem Cells, Mesenchymal-Derived Cells and Immune Cells in Muscle Homeostasis, Regeneration and Disease,” Cell Death & Disease 6, no. 7 (2015): e1830–e1830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhang P, Su J, and Mende U, “Cross Talk Between Cardiac Myocytes and Fibroblasts: From Multiscale Investigative Approaches to Mechanisms and Functional Consequences,” American Journal of Physiology. Heart and Circulatory Physiology 303, no. 12 (2012): H1385–H1396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Nakamura R, Doyle C, Bing R, Johnson AM, and Branski RC, “Preliminary Investigation of In Vitro, Bidirectional Vocal Fold Muscle-Mucosa Interactions,” Annals of Otology, Rhinology, and Laryngology 131, no. 5 (2022): 512–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kim KK, Sheppard D, and Chapman HA, “TGF-β1 Signaling and Tissue Fibrosis,” Cold Spring Harbor Perspectives in Biology 10, no. 4 (2018): a022293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.McPherron AC and Lee SJ, “Double Muscling in Cattle due to Mutations in the Myostatin Gene,” Proceedings of the National Academy of Sciences of the United States of America 94, no. 23 (1997): 12457–12461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yoshimatsu M, Nakamura R, Bing R, Gartling GJ, and Branski RC, “Smad2/3 Signaling Mediates the Atrophic Response in Vocal Fold Myoblasts In Vitro,” Laryngoscope 136, no. 1 (2026): 291–303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Branski RC, Barbieri SS, Weksler BB, et al. , “Effects of Transforming Growth Factor-β1 on Human Vocal Fold Fibroblasts,” Annals of Otology, Rhinology, and Laryngology 118, no. 3 (2009): 218–226. [DOI] [PubMed] [Google Scholar]
  • 19.Velasco-Mallorqú F, Fernández JM, Fernández-Costa F, et al. , “New Volumetric CNT-Doped Gelatin-Cellulose Scaffolds for Skeletal Muscle Tissue Engineering,” Nanoscale Advances 2, no. 7 (2020): 2885–2896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Valle-Tenney R, Rebolledo DL, Lipson KE, and Brandan E, “Role of Hypoxia in Skeletal Muscle Fibrosis: Synergism Between Hypoxia and TGF-β Signaling Upregulates CCN2/CTGF Expression Specifically in Muscle Fibers,” Matrix Biology 87 (2020): 48–65. [DOI] [PubMed] [Google Scholar]
  • 21.Samarakoon R and Higgins PJ, “Integration of Non-SMAD and SMAD Signaling in TGF-β1-Induced Plasminogen Activator Inhibitor Type-1 Gene Expression in Vascular Smooth Muscle Cells,” Thrombosis and Haemostasis 100, no. 6 (2008): 976. [PMC free article] [PubMed] [Google Scholar]
  • 22.Lokireddy S, Mouly V, Butler-Browne G, et al. , “Myostatin Promotes the Wasting of Human Myoblast Cultures Through Promoting Ubiquitin-Proteasome Pathway-Mediated Loss of Sarcomeric Proteins,” American Journal of Physiology-Cell Physiology 301, no. 6 (2011): 1316–1324. [DOI] [PubMed] [Google Scholar]
  • 23.Zhao T and Su Y, “Mechanisms and Therapeutic Potential of Myofi-broblast Transformation in Pulmonary Fibrosis,” Journal of Respiratory Biology and Translational Medicine 2, no. 1 (2025): 10001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang X, McLennan SV, Allen TJ, and Twigg SM, “Regulation of Pro-Inflammatory and Pro-Fibrotic Factors by CCN2/CTGF in H9c2 Cardiomyocytes,” Journal of Cell Communication and Signaling 4, no. 1 (2010): 15–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ghosh AK and Vaughan DE, “PAI-1 in Tissue Fibrosis,” Journal of Cellular Physiology 227, no. 2 (2012): 493–507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Livak KJ and Schmittgen TD, “Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method,” Methods 25, no. 4 (2001): 402–408. [DOI] [PubMed] [Google Scholar]
  • 27.Ohno T, Hirano S, and Rousseau B, “Gene Expression of Transforming Growth Factor-β1 and Hepatocyte Growth Factor During Wound Healing of Injured Rat Vocal Fold,” Laryngoscope 119, no. 4 (2009): 806–810. [DOI] [PubMed] [Google Scholar]
  • 28.Leydon C, Imaizumi M, Bartlett RS, Wang SF, and Thibeault SL, “Epithelial Cells Are Active Participants in Vocal Fold Wound Healing: An In Vivo Animal Model of Injury,” PLoS One 9, no. 12 (2014): e115389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Cartledge JE, Kane C, Dias P, et al. , “Functional Crosstalk Between Cardiac Fibroblasts and Adult Cardiomyocytes by Soluble Mediators,” Cardiovascular Research 105, no. 3 (2015): 260–270. [DOI] [PubMed] [Google Scholar]
  • 30.Krieger J, Park BW, Lambert CR, and Malcuit C, “3D Skeletal Muscle Fascicle Engineering Is Improved With TGF-β1 Treatment of Myogenic Cells and Their Co-Culture With Myofibroblasts,” PeerJ 6, no. 7 (2018): e4939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhang Y, Li H, Lian Z, and Li N, “Myofibroblasts Protect Myoblasts From Intrinsic Apoptosis Associated With Differentiation via β1 Integrin-PI3K/Akt Pathway,” Development, Growth & Differentiation 52, no. 8 (2010): 725–733. [DOI] [PubMed] [Google Scholar]
  • 32.Fry CS, Kirby TJ, Kosmac K, McCarthy JJ, and Peterson CA, “Myogenic Progenitor Cells Control Extracellular Matrix Production by Fibroblasts During Skeletal Muscle Hypertrophy,” Cell Stem Cell 20, no. 1 (2017): 56–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hidalgo V, Kastury N, Durham CW, et al. , “Co-Culture With Normal and Senescent AC16 Cardiomyocytes Modulates Fibrotic Response in Primary Human Ventricular Fibroblasts,” microPublication Biology 10 (2023): 17912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Nanri Y, Nunomura S, Terasaki Y, et al. , “Cross-Talk Between Transforming Growth Factor-β and Periostin Can be Targeted for Pulmonary Fibrosis,” American Journal of Respiratory Cell and Molecular Biology 62, no. 2 (2020): 204–216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kost KM and Sataloff RT, “Voice Disorders in the Elderly,” Clinics in Geriatric Medicine 34, no. 2 (2018): 191–203. [DOI] [PubMed] [Google Scholar]
  • 36.Chargé SBP and Rudnicki MA, “Cellular and Molecular Regulation of Muscle Regeneration,” Physiological Reviews 84, no. 1 (2004):209–238. [DOI] [PubMed] [Google Scholar]
  • 37.Lee K, Kletzien H, Connor NP, Schultz E, Chamberlain CS, and Bless DM, “Effects of Aging on Thyroarytenoid Muscle Regeneration,” Laryngoscope 122, no. 12 (2012): 2800–2807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Zammit PS, Partridge TA, and Yablonka-Reuveni Z, “The Skeletal Muscle Satellite Cell: The Stem Cell That Came in From the Cold,” Journal of Histochemistry and Cytochemistry 54, no. 11 (2006): 1177–1191. [DOI] [PubMed] [Google Scholar]
  • 39.Zhou X, Wang JL, Lu J, et al. , “Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival,” Cell 142, no. 4 (2010): 531–543. [DOI] [PubMed] [Google Scholar]
  • 40.Agapova OA, Fang Y, Sugatani T, Seifert ME, and Hruska KA, “Ligand Trap for the Activin Type IIA Receptor Protects Against Vascular Disease and Renal Fibrosis in Mice With Chronic Kidney Disease,” Kidney International 89, no. 6 (2016): 1231–1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Winbanks CE, Weeks KL, Thomson RE, et al. , “Follistatin-Mediated Skeletal Muscle Hypertrophy Is Regulated by Smad3 and mTOR Independently of Myostatin,” Journal of Cell Biology 197, no. 7 (2012): 997–1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Maeshima A, Mishima K, Yamashita S, et al. , “Follistatin, an Activin Antagonist, Ameliorates Renal Interstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction,” BioMed Research International 2014 (2014): 376191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Fukushima K, Badlani N, Usas A, Riano F, Fu FH, and Huard J, “The Use of an Antifibrosis Agent to Improve Muscle Recovery After Laceration,” American Journal of Sports Medicine 29, no. 4 (2001):394–402. [DOI] [PubMed] [Google Scholar]
  • 44.Morikawa M, Derynck R, and Miyazono K, “TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology,” Cold Spring Harbor Perspectives in Biology 8, no. 5 (2016): a021873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Luo K, “Signaling Cross Talk Between TGF-β/Smad and Other Signaling Pathways,” Cold Spring Harbor Perspectives in Biology 9, no. 1 (2017): a022137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Lam AP and Gottardi CJ, “β-Catenin Signaling: A Novel Mediator of Fibrosis and Potential Therapeutic Target,” Current Opinion in Rheumatology 23, no. 6 (2011): 562–567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Suzuki A, Pelikan RC, and Iwata J, “WNT/β-Catenin Signaling Regulates Multiple Steps of Myogenesis by Regulating Step-Specific Targets,” Molecular and Cellular Biology 35, no. 10 (2015): 1763–1776. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

RESOURCES